Research on brain-derived blood EV research in MS, particularly focusing on L1CAM, alongside other subpopulations such as GLAST and MOG, has gained attention recently, primarily examining the potential of these EVs as biomarkers in relation to disease status and treatment response [3,22,23,24,25,26,27]. This evidence concerns the gene SLC1A3 and myeloid sarcoma.